Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, Stournaras C, Castanas E
Efficacy of Incretin Receptor Agonists in Tissue-Specific Fibrotic Inflammatory Disorders 3.1
To view or add a comment, sign in Novartis has announced positive Phase III results for its oral complement-pathway inhibitor Fabhalta (iptacopan) in adults with IgA nephropathy (IgAN) demonstrating a statistically significant and clinically meaningful slowing of kidney function decline versus placebo
Respiratory Syncytial Virus (RSV) vaccines are acceptable
Want the full conversation
Compounded GLP-1s Under Fire: Legal actions and regulatory guidance may cause these alternatives to disappear in the near future
US$ 24.90
US$ 20.00
US$ 23.80
US$ 28.94
US$ 27.00
US$ 25.51
US$ 24.83
US$ 29.06
US$ 27.32
